Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

enVVeno Medical (NVNO) Change in Accured Expenses (2017 - 2020)

enVVeno Medical has reported Change in Accured Expenses over the past 4 years, most recently at $660194.0 for Q4 2020.

  • For Q4 2020, Change in Accured Expenses rose 495.97% year-over-year to $660194.0; the TTM value through Dec 2020 reached $614428.0, up 1178.7%, while the annual FY2025 figure was $1000.0, 99.86% down from the prior year.
  • Change in Accured Expenses for Q4 2020 was $660194.0 at enVVeno Medical, up from -$169737.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $670878.0 in Q2 2018 and troughed at -$524672.0 in Q3 2018.
  • A 4-year average of $47140.6 and a median of $29374.0 in 2019 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 356.58% in 2018 and later soared 495.97% in 2020.
  • Year by year, Change in Accured Expenses stood at $86701.0 in 2017, then crashed by 356.58% to -$222460.0 in 2018, then grew by 25.05% to -$166728.0 in 2019, then soared by 495.97% to $660194.0 in 2020.
  • Business Quant data shows Change in Accured Expenses for NVNO at $660194.0 in Q4 2020, -$169737.0 in Q3 2020, and $94105.0 in Q2 2020.